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Antipsychotic drugs are one of the largest types of prescribed drugs and have large
inter-individual differences in efficacy, but there is no methodology to predict their clinical
effect. Here we show a four-gene blood expression profile to predict the response to
antipsychotics in schizophrenia patients before treatment. We sequenced total mRNA
from blood samples of antipsychotic naïve patients who, after 3 months of treatment,
were in the top 40% with the best response (15 patients) and in the bottom 40%
with the worst response (15 patients) according to the Brief Psychiatric Rating Scale
(BPRS). We characterized the transcriptome before treatment of these 30 patients and
found 130 genes with significant differential expression (Padj value < 0.01) associated
with clinical response. Then, we used Random Forests, an ensemble learning method
for classification and regression, to obtain a list of predictor genes. The expression
of four genes can predict the response to antipsychotic medication with a cross-
validation accuracy estimation of 0.83 and an area under the curve of 0.97 using a
logistic regression. We anticipate that this approach is a gateway to select the specific
antipsychotic that will produce the best response to treatment for each specific patient.
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INTRODUCTION
Antipsychotic medications are the mainstay of schizophrenia treatment (Insel, 2010). They are
also used for several other clinical conditions (i.e., other psychoses, bipolar disorder, delirium,
depression, personality disorders, dementia and autism; Alexander et al., 2011; Carton et al., 2015;
Roberts et al., 2016) and are therefore one of the most widely used and costly types of drugs having
experienced a significant increase in overall prescription in recent years (Kantor et al., 2015).
Unfortunately, only 55%–60% of first episode patients will have significantly reduced the severity
of their psychopathology with adequate doses of antipsychotic drugs (Crespo-Facorro et al., 2007)
and 30% of patients will fail to respond to two antipsychotics after adequate trials (Meltzer, 1997;
Zhang and Malhotra, 2011; Pouget et al., 2014). Research to find predictors of the response to
antipsychotic treatment is an old field of psychiatry; however, despite decades of research to
find clinical biomarkers, there is not a useful molecular test available to predict the response
to treatment (Prata et al., 2014). In a previous study (Crespo-Facorro et al., 2015), we analyzed
the blood transcriptome of 22 schizophrenia patients before and after medication with atypical
antipsychotics and we found that 17 genes had significantly altered expression after medication
(P value adjusted < 0.05). With the goal of generating an expression profile that could predict
the outcome of treatment, we characterized the transcriptome of a drug-naïve (before any dose of
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TABLE 1 | Sociodemographic and clinical characteristics of study individuals.
Characteristics Total Best-Responders Worst-Responders
(n = 30) (n = 15) (n = 15)
Mean SD Mean SD Mean SD
Age at admission (years) 29.6 10.5 29.3 11.7 29.9 9.6
Age at psychosis onset (years) 28.6 10.4 28.7 11.7 28.5 9.4
Duration of untreated psychosis (months) 16.4 23.8 14.9 25.5 18.0 22.9
Duration of untreated illness (months) 12.0 17.8 7.9 10.9 16.1 22.3
BPRS at admission 74.1 15.4 83.5 8.9 64.8 15.0
BPRS at 3 months of treatment 34.6 11.8 29.7 5.2 39.5 14.4
antipsychotic medication was taken) cohort of 37 first episode
schizophrenia patients. Patients were then divided into
two groups according to their response after 3 months of
antipsychotic treatment according to their Brief Psychiatric
Rating Scale (BPRS; Lukoff et al., 1986) total scores: the first
group included the top 40% of patients who had the best
response to treatment (highest absolute decrease of BPRS score)
further referred to as ‘‘best-responders’’, and the other group
included the bottom 40% of patients with the worst response
(lower absolute decrease of BPRS score) further referred to as
‘‘worst-responders’’ (Table 1). The transcriptomes at baseline of
both groups were compared using the program Deseq (Anders
and Huber, 2010) to define the genes with significant differential
expression.
MATERIALS AND METHODS
Study Setting and Subjects
The cohort analyzed in this study was obtained from an ongoing
epidemiological and 3-year longitudinal intervention program
of first-episode psychosis (PAFIP) conducted at the outpatient
clinic and the inpatient unit at the University Hospital Marques
de Valdecilla (Cantabria, Spain). Conforming to international
standards for research ethics, this study was approved by the
Cantabria Ethics Institutional Review Board (IRB). Patients
meeting inclusion criteria and their families provided written
informed consent to be included in the PAFIP. The biological
samples of patients included in the study were provided by the
Valdecilla biobank.
All referrals to PAFIP were screened for patients who met
the following criteria: (1) 15–60 years old; (2) living in the
catchment area (Cantabria); (3) experiencing a first episode
of psychosis; (4) having received no prior treatment with
antipsychotic medication; (5) DSM-IV criteria for schizophrenia,
schizophreniform disorder, schizoaffective disorder, or brief
psychotic disorder. Patients were excluded for any of the
following reasons: (1) meeting DSM-IV criteria for drug
dependence; (2) meeting DSM-IV criteria for mental retardation;
and (3) having a history of neurological disease or head injury.
Only patients with a history of drug dependence (DSM-IV
diagnosis; but not drug abuse) during the last 12 months were
excluded of the study. The diagnoses were confirmed using the
Structured Clinical Interview for DSM-IV (SCID–I) carried out
by an experienced psychiatrist 6 months on from the baseline
visit. Our operational definition for a ‘‘first episode of psychosis’’
includes individuals with a non-affective psychosis (meeting
the inclusion criteria defined above) who have not previously
received antipsychotic treatment regardless the duration of
psychosis. The 37 individuals who gave written consent to their
participation in the program, who fulfilled inclusion criteria at
6 months, and had mRNA samples at baseline and at 3 months,
were included in our analyses.
After informed consent was signed, patients were included in
a prospective, randomized, flexible-dose, open-label study
(EudraCT number 2013-005399-16). We used a simple
randomization procedure. At study intake, all patients were
antipsychotic naïve and were randomized to aripiprazole
(N = 17), risperidone (N = 20). Initial dose ranges were
5–10 mg/day of aripiprazole and 1–2 mg/day of risperidone.
Rapid titration schedule (5-day), until optimal dose was reached,
was used as a rule unless severe side effects occurred. Dose range
was 5–30 mg/day aripiprazole and 2–6 mg risperidone. The dose
and type of antipsychotic medication could be changed, at the
physician’s discretion, based on clinical efficacy and the profile
of side effects during the follow-up period. Initial prescribed
medications should be switched to olanzapine (range dose
5–20 mg) due to lack of clinical response at 3 weeks (less than
30% of total BPRS score reduction and CGI ≥ 5) or persisting
distressing adverse drug reactions. For patients who fail to reach
a clinical response after two anti-psychotic agents, clozapine
should be started. However, despite this recommendation,
clozapine treatment should not be commenced at clinician’s
discretion.
For the present investigation, drug-naïve first episode patients
were divided into two groups based on their clinical response
after 3 months of antipsychotic treatment according to their
BPRS (Lukoff et al., 1986) total scores: the first group included
the top 40% of patients who had the best response to treatment
(highest absolute decrease of BPRS score) and are referred to as
‘‘best-responders’’, and the other group included the bottom 40%
of patients with the worst response (lower absolute decrease of
BPRS score) and are referred to as ‘‘worst-responders’’.
At 3-month follow-up patients were on: Aripiprazole
(7 worst-responders; 3 best-responders), Risperidone (5 worst-
responders; 8 best-responders), Olanzapine (3 worst-responders;
4 best-responders).
No statistically significant differences between the
two groups (best vs. worst clinical response patients) with
respect to percentage of concomitant use of antidepressants,
antimuscarinics, hypnotics and benzodiazepines at 3 months
were observed (all p’s > 0.542). After 6 months follow-up
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patients were diagnosed as follows, in the group of patients with
the best-response to antipsychotic treatment: nine schizophrenia,
four schizophreniform disorder, one brief psychotic disorder,
and one schizoaffective disorder; in the group of patients with
worst-response to antipsychotic treatment: nine schizophrenia,
four schizophreniform disorder and two brief psychotic disorder.
No significant differences between groups were either found.
Premorbid and Sociodemographic
Variables
Premorbid and sociodemographic information was collected
from patients (Table 1), relatives and previous medical records.
Age of onset of psychosis was defined as the age when the
emergence of the first continuous psychotic symptom occurred.
Duration of untreated psychosis (DUP) was defined as the
time from the first psychotic symptom to the initiation of
antipsychotic drug treatment. Duration of untreated illness
(DUI) was defined as the time from the first unspecific symptoms
related to psychosis to the initiation of antipsychotic drug
treatment.
Laboratory Assessments
To minimize the effects of diet and technique, blood samples
were obtained from fasting subjects from 8:00 to 10:00 a.m. by the
same staff, in the same setting. None of the patients had a chronic
inflammation or infection, or were taking medication that could
influence the results of blood tests.
RNA Extraction
Total RNA was extracted from blood using the TempusTM Blood
RNA Tube and TempusTM Spin RNA Isolation Kit (Applied
Biosystems, Foster City, CA, USA) following the manufacturer
protocols. To define expression profiles, a key factor is that
the RNA is intact. To select only high-quality RNA, the RNA
Integrity Number (RIN) was characterized with a Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA) and samples with a
RIN of at least 7.2 were selected. The selected samples have RINs
that range from 8 to 10 with an average of 9.11.
RNA Next Generation Sequencing
Total RNA was extracted from peripheral whole blood of each
individual. The mRNA obtained from blood was sequenced
at the Centro Nacional de Análisis Genómico (CNAG) using
Illumina HiSeq instruments (San Diego, CA, USA). The mRNA
was isolated from the total RNA and was fragmented once
transformed into cDNA. Fragments of 300 bp on average were
selected to construct the libraries for sequencing. Pair-end
sequences of 70 nucleotides for each end were produced.
Alignment of Reads to the Human Genome
Reference
Alignment of the reads was performed in an SLURMHPC server
running Tophat 2.0.6 with default options (Trapnell et al., 2009).
Tophat aligns RNA-Seq reads to genomes using the Bowtie
2.0.2 alignment program (Langmead et al., 2009), and then
analyses the mapping results to identify splice junctions between
exons.
Differential Expression Statistical Analyses
Bedtools 2.17.0 (multicov option; Quinlan and Hall, 2010) was
used to count the amount of reads mapped to each gene. The
Reference Sequence (RefSeq) gene coordinates were defined
using the RefFlat file from the UCSC Genome Bioinformatics
Site (as February 28th, 2014). DESeq 1.4 package (Anders and
Huber, 2010), setting up fit-only as fitting method, was used to
test for differential expression using gene-count data. Two sided
Fisher tests were carried out to identify functional enrichment of
biological annotations.
Prediction Method
Gene selection was performed with the implementation of
Random Forest method in the Random Forest 4.6-12 package
(Breiman, 2001) of R. Expression values of the 130 genes with
significantly different expression between the best-responders
and worst-responders was used as input with default parameters.
Genes with the best Gini were selected for the predictor. It
was trained using Logistic regression (Cox, 1958) with the glm
function of R 3.2.3 and the calculation of the estimated cross-
validation was performed with the cv.glm function of boot
package which implements bootstrapping methods (Hinkley,
1988).
RESULTS
Differential Gene Expression Between
Best-Responders and Worst-Responders
Before Treatment
We found 130 genes with significant differential expression
between the best-responders and the worst-responders
(Padj value < 0.01; Supplementary Table S1). These genes
were significantly enriched for schizophrenia related genes
according to the scientific literature in the Gene Reference into
Function (GeneRIF) database (Mitchell et al., 2003). We found
14 schizophrenia differential expression genes between the
best-responders and the worst-responders (13.4% observed vs.
6.8% expected; Fisher P value = 0.016).
Differential Gene Expression Between the
Best-Responders and the
Worst-Responders After Treatment
To obtain more information, we sequenced the transcriptome
of the patients after 3 months of treatment with antipsychotics.
We defined 219 differential expression genes between the
best-responders and the worst-responders after 3 months
of medication (Supplementary Table S2). These genes were
enriched significantly for schizophrenia (21 genes or 11.3% vs.
6.8%; Fisher P value = 0.027). After 3 months of medication
with antipsychotics, 6 out of the 14 schizophrenia-annotated
genes with differential expression before medication between
the best-responders and the worst-responders no longer had
differential expression: VWF, a glycoprotein with increased
levels in plasma of non-medicated patients and in bipolar
disorder and schizophrenia compared to control individuals
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(Yri et al., 2012); UGT1A1, a gene with promoter variations
in patients with schizophrenia that result in lower serum
bilirubin levels (Vitek et al., 2010); HMOX1, an enzyme that
has anti-inflammatory properties and mediates the first step
of heme catabolism involved in the production of carbon
monoxide, a putative neurotransmitter, is over-expressed in
transgenic mice with schizophrenia-like features (Song et al.,
2012); IL8 (also known as CXCL8), a chemokine with altered
expression in the dorsolateral prefrontal cortex of individuals
with schizophrenia (Fillman et al., 2013); NTNG2, a gene with
haplotypes associated with schizophrenia and isoform expression
significantly different in schizophrenic and control brains (Aoki-
Suzuki et al., 2005); and PTGDS, a prostaglandin that acts as
a neuromodulator as well as a trophic factor in the central
nervous system and was studied as a schizophrenia candidate
(Ruano et al., 2007) and with reduced mRNA expression
in peripheral blood of bipolar disorder patients compared
with healthy control subjects (Munkholm et al., 2015). The
differential expression genes between the best-responders and
the worst-responders after 3 months of medication indicates
that 5 out the 11 genes involved in ‘‘drug processing’’ with
differential expression before medication still had differential
expression and similar expression profile after medication. These
five genes are:GSTM1, a glutathione S-transferase involved in the
detoxification of electrophilic compounds, such as therapeutic
drugs, by conjugation with glutathione, with genetic variations
that affect the toxicity and efficacy of certain drugs (Li et al.,
2013); THBS1, an adhesive glycoprotein that mediates cell-
to-cell and cell-to-matrix interactions and related to drug
resistance (Rath et al., 2006); PRAME, an antigen related to
cytotoxic drug sensitivity (Kewitz and Staege, 2013); GSTT1, a
glutathione S-transferase that functions as a drug metabolizing
enzyme (Yri et al., 2012); and SLC22A16, a solute carrier
reported to be involved in drug response (Aouida et al.,
2010).
Differential Gene Expression of the
Best-Responders Before and After
Treatment and of the Worst-Responders
Before and After Treatment
We also compared the transcriptome of the best-responders
before and after medication and characterized 176 genes with
differential expression (Supplementary Table S3). These genes
were also enriched for schizophrenia annotations (9.4% observed
vs. 6.7% expected). When we defined the differential expression
genes of the worst-responders, before and after medication,
we found only 23 genes (Supplementary Table S4) and these
were not enriched for schizophrenia annotations (5.2% vs.
6.7%). These data indicate that the individuals that respond
worst to treatment have fewer altered genes (a 7.6 fold
decrease) in their expression by antipsychotics than the best-
responders.
Predictor Test
To generate a predictor test before medication of response
to antipsychotics, we analyzed all 130 genes with significantly
different expression between the best-responders and the worst-
responders using Random Forests, an ensemble learning method
for classification and regression, among other tasks, that operates
by constructing a multitude of decision trees (Díaz-Uriarte and
Alvarez de Andrés, 2006; Koo et al., 2013). Functional analyses
of the 30 genes with the highest predictive power (Figure 1;
Supplementary Table S5) indicated a significant enrichment
of genes related to schizophrenia (29.2% observed vs. 6.9%
expected; Fisher P value = 0.0009) and bipolar disorder (16.7%
vs. 2.6%; Fisher P value = 0.003). In the complete list of
130 genes, the enrichment for schizophrenia genes was smaller
(13.4%).
Using logistic regression we defined the area under the curve
(AUC), representing the combined predictive power of the genes,
and a cross-validation estimate of accuracy for the prediction
using the first two, three and four genes. We found that the
prediction using two genes (SLC9A3 and HMOX1) had an
area under the curve of 0.92 and a cross-validation estimate of
accuracy of 0.73; with three genes (adding SLC22A16) the values
were 0.96 and 0.833 respectively; and with four genes (adding
LOC284581) they were 0.97 and 0.833 respectively (Figure 2).
These data indicate that a test with the top four or three of the
most predictive genes could be an appropriate choice.
DISCUSSION
We found a significantly different number of schizophrenia
differential expression genes between the groups of
best-responders and worst-responders, suggesting that the
response to treatment could be due, at least partially, to the fact
FIGURE 1 | Variable Importance (Gini) for the top 30 predictor genes. Gini
variable importance measures reflect the mean decrease in impurity by splits
of a given variable in the classification tree, weighted by the proportion of
samples reaching that node. A greater “mean decrease Gini” indicates that the
gene plays a greater role in partitioning the data into the defined classes.
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FIGURE 2 | Receiver operating characteristic (ROC) curves. (A) Using the best two genes (HMOX1, SCL9A3) to train the predictor we obtain a ROC with an area
under the curve (AUC) of 0.92. (B) Using the best three genes (HMOX1, SCL9A3, SLC22A16) to train the predictor we obtain a ROC with an AUC of 0.96. (C) Using
the best four genes (HMOX1, SCL9A3, SLC22A16, LOC284581) to train the predictor we obtain a ROC with an AUC of 0.97.
that the two groups of patients analyzed have different genetic
background causing schizophrenia.
Our results indicate that 6 out of the 14 schizophrenia-
annotated genes with differential expression before medication
between the best and worst-responders had no longer differential
expression after 3 months of medication. These six genes
are excellent candidates to be the targets used by the drugs
to improve the symptoms of schizophrenia. The data show
that the group of best-responders has a significant enrichment
of schizophrenia-annotated genes with differential expression
before and after 3 months of medication. However, we do not
observe this significant enrichment of schizophrenia-annotated
genes in the group of worst-responders, suggesting that the
efficacy of antipsychotics is dependent of the expression profile
of the patient before medication and that a predictor could
be generated using a gene expression profile of untreated
patients.
With the purpose of finding genes that can predict the
response to antipsychotics, we characterized 130 genes with
differential expression between the best and worst responders
before treatment. We found that the 30 genes with the
highest predictive power among these 130 genes, had a higher
enrichment of schizophrenia-annotated genes, indicating that
genes related to schizophrenia tend to have a higher predictive
value. This would suggest that schizophrenia genes are involved
in the response and that the schizophrenia causative genes tend
to be different between the best-responders and the worst-
responders.
We tested the predictive power of the top four predictor genes
in our patients, and found that the test would accurately predict
93% of the worst-responders and 87% of the best-responders
(Figure 3). The gene with the highest predictive value, SLC9A3,
is a Na/H exchanger and belongs to several pathways such
as the transmembrane transportation of small molecules and
the SLC-mediated transmembrane transport that facilitate the
movement of a specific substrate either against or following their
concentration gradient. Currently, there are novel drugs being
developed targeting SLC9A3 that could be of interest for the field
FIGURE 3 | Predicted probability of response to antipsychotics using a
4-gene test. Scatter plot, which represents the predicted probability of
response (y-axis) for each input sample (x-axis) in the logistic regression
predictor. Red points represent worst-responder patients and black points
represent best-responder patients.
of schizophrenia (Dominguez Rieg et al., 2016). The second best
predictor isHMOX1, or Heme oxygenase, an essential enzyme in
heme catabolism, that cleaves heme to form biliverdin, which is
subsequently converted to bilirubin by biliverdin reductase, and
carbon monoxide, a putative neurotransmitter. The relationship
of this gene with the generation of a neurotransmitter could
explain the relationship of his expression with the response to
antipsychotics and open the gate to possible medical actions. The
previous observations are consistent with the fact that the mouse
homologous gene has been related to schizophrenia-like features
in transgenic mice, what can facilitate new therapeutics for
schizophrenia (Song et al., 2012). HMOX1 has been also related
to drug resistance in acute myeloid leukemia (Zhe et al., 2015).
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The third predictor, SLC22A16, encodes a member of the organic
zwitterion transporter protein family which transports carnitine.
The encoded protein has also been shown to be involved in
the transport of anticancer drugs such as bleomycin (Aouida
et al., 2010) and successful treatment has been correlated with
the level of activity of this transporter in tumor cells. Variant
alleles of SLC22A16 are associated with response and levels of
toxicity caused by doxorubicin and cyclophosphamide therapy
in the treatment of breast cancer which is consistent with the
fact that doxorubicin is a substrate this transporter (Bray et al.,
2010). Interestingly, SLC22A16 is located within a schizophrenia
susceptibility locus in chromosome 6q (Cao et al., 1997). The
fourth gene, LOC284581, is not annotated but it maps within
a Parkinson’s disease locus of 15.8 Mb (Satake et al., 2009).
Interestingly, all three annotated genes are involved in drug
resistance, toxicity or transportation and offer new possibilities
to generate therapeutic actions for schizophrenia.
A potential limitation of the study is the small sample size
(n = 30 or n = 15 per group). However, we are not aware of
any full transcriptome study on drug-naïve patients (not having
received a single dose of antipsychotics) that had studied similar
or higher number of samples than our study. Besides, our study
sample size is larger than in most studies based on RNASeq
data (according to the mean of samples reported by the Gene
Expression Omnibus database). A possible confounding factor
could be the cannabis use that has been reported to enhance
negative outcomes such as suicidal risk (Serafini et al., 2012).
However, it is unlikely that this factor could affect the results
of our study given that only eight patients reported as cannabis
users and were equally divided in both groups, four in the
best-responders and four in the worst-responders. The data we
are presenting here is a first step to generate a simple test
(expression levels of a small number of genes) to predict the
response to antipsychotics, one of the most prescribed types of
drugs worldwide, and to provide a tool to select the antipsychotic
expected to generate the best clinical response.
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